Synergistic antitumor effects of radiation and proteasome inhibitor treatment in pancreatic cancer through the induction of autophagy and the downregulation of TRAF6

Hui Wen Chiu, Shu Wen Lin, Li Ching Lin, Yung Ho Hsu, Yuh Feng Lin, Sheng Yow Ho, Yuan-Hua Wu, Ying-Jan Wang

研究成果: Article

21 引文 (Scopus)

摘要

Ninety percent of human pancreatic cancer is characterized by activating K-RAS mutations. TRAF6 is an oncogene that plays a vital role in K-RAS-mediated oncogenesis. We investigated the synergistic effect of combining ionizing radiation (IR) and proteasome inhibitor (MG132). Furthermore, following combined treatment with IR and MG132, we analyzed the expression of TRAF6 and the mechanism of human pancreatic cancer cell death in vitro and in an orthotopic pancreatic cancer mouse model. The combined treatment groups displayed synergistic cell killing effects and induced endoplasmic reticulum stress in human pancreatic cancer cells. The combined treatment groups were characterized by enhanced cytotoxicity, which resulted from increased autophagy induction through the inhibition of TRAF6. Significantly reduced cytotoxicity was observed following MG132 and IR treatment of MIA PaCa-2 cells pre-treated with 3-MA (an autophagy inhibitor). Down-regulation of TRAF6 led to a significant increase in apoptosis and autophagy. In an orthotopic xenograft model of SCID mice, combination MG132 and IR therapy resulted in a significant increase in the tumor growth delay time and a decreased tumor tissue expression of TRAF6. IR combined with a proteasome inhibitor or TRAF6 inhibition could represent a new therapeutic strategy for human pancreatic cancer.

原文English
頁(從 - 到)229-239
頁數11
期刊Cancer Letters
365
發行號2
DOIs
出版狀態Published - 2015 九月 1

指紋

TNF Receptor-Associated Factor 6
Proteasome Inhibitors
Radiation Effects
Autophagy
Pancreatic Neoplasms
Ionizing Radiation
Down-Regulation
Therapeutics
Endoplasmic Reticulum Stress
SCID Mice
Oncogenes
Heterografts
Neoplasms
Carcinogenesis
Cell Death
Radiotherapy
Apoptosis
Mutation
benzyloxycarbonylleucyl-leucyl-leucine aldehyde
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

引用此文

Chiu, Hui Wen ; Lin, Shu Wen ; Lin, Li Ching ; Hsu, Yung Ho ; Lin, Yuh Feng ; Ho, Sheng Yow ; Wu, Yuan-Hua ; Wang, Ying-Jan. / Synergistic antitumor effects of radiation and proteasome inhibitor treatment in pancreatic cancer through the induction of autophagy and the downregulation of TRAF6. 於: Cancer Letters. 2015 ; 卷 365, 編號 2. 頁 229-239.
@article{a44c6081efbf4ae59bea13c81b9fe12c,
title = "Synergistic antitumor effects of radiation and proteasome inhibitor treatment in pancreatic cancer through the induction of autophagy and the downregulation of TRAF6",
abstract = "Ninety percent of human pancreatic cancer is characterized by activating K-RAS mutations. TRAF6 is an oncogene that plays a vital role in K-RAS-mediated oncogenesis. We investigated the synergistic effect of combining ionizing radiation (IR) and proteasome inhibitor (MG132). Furthermore, following combined treatment with IR and MG132, we analyzed the expression of TRAF6 and the mechanism of human pancreatic cancer cell death in vitro and in an orthotopic pancreatic cancer mouse model. The combined treatment groups displayed synergistic cell killing effects and induced endoplasmic reticulum stress in human pancreatic cancer cells. The combined treatment groups were characterized by enhanced cytotoxicity, which resulted from increased autophagy induction through the inhibition of TRAF6. Significantly reduced cytotoxicity was observed following MG132 and IR treatment of MIA PaCa-2 cells pre-treated with 3-MA (an autophagy inhibitor). Down-regulation of TRAF6 led to a significant increase in apoptosis and autophagy. In an orthotopic xenograft model of SCID mice, combination MG132 and IR therapy resulted in a significant increase in the tumor growth delay time and a decreased tumor tissue expression of TRAF6. IR combined with a proteasome inhibitor or TRAF6 inhibition could represent a new therapeutic strategy for human pancreatic cancer.",
author = "Chiu, {Hui Wen} and Lin, {Shu Wen} and Lin, {Li Ching} and Hsu, {Yung Ho} and Lin, {Yuh Feng} and Ho, {Sheng Yow} and Yuan-Hua Wu and Ying-Jan Wang",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.canlet.2015.05.025",
language = "English",
volume = "365",
pages = "229--239",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Synergistic antitumor effects of radiation and proteasome inhibitor treatment in pancreatic cancer through the induction of autophagy and the downregulation of TRAF6. / Chiu, Hui Wen; Lin, Shu Wen; Lin, Li Ching; Hsu, Yung Ho; Lin, Yuh Feng; Ho, Sheng Yow; Wu, Yuan-Hua; Wang, Ying-Jan.

於: Cancer Letters, 卷 365, 編號 2, 01.09.2015, p. 229-239.

研究成果: Article

TY - JOUR

T1 - Synergistic antitumor effects of radiation and proteasome inhibitor treatment in pancreatic cancer through the induction of autophagy and the downregulation of TRAF6

AU - Chiu, Hui Wen

AU - Lin, Shu Wen

AU - Lin, Li Ching

AU - Hsu, Yung Ho

AU - Lin, Yuh Feng

AU - Ho, Sheng Yow

AU - Wu, Yuan-Hua

AU - Wang, Ying-Jan

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Ninety percent of human pancreatic cancer is characterized by activating K-RAS mutations. TRAF6 is an oncogene that plays a vital role in K-RAS-mediated oncogenesis. We investigated the synergistic effect of combining ionizing radiation (IR) and proteasome inhibitor (MG132). Furthermore, following combined treatment with IR and MG132, we analyzed the expression of TRAF6 and the mechanism of human pancreatic cancer cell death in vitro and in an orthotopic pancreatic cancer mouse model. The combined treatment groups displayed synergistic cell killing effects and induced endoplasmic reticulum stress in human pancreatic cancer cells. The combined treatment groups were characterized by enhanced cytotoxicity, which resulted from increased autophagy induction through the inhibition of TRAF6. Significantly reduced cytotoxicity was observed following MG132 and IR treatment of MIA PaCa-2 cells pre-treated with 3-MA (an autophagy inhibitor). Down-regulation of TRAF6 led to a significant increase in apoptosis and autophagy. In an orthotopic xenograft model of SCID mice, combination MG132 and IR therapy resulted in a significant increase in the tumor growth delay time and a decreased tumor tissue expression of TRAF6. IR combined with a proteasome inhibitor or TRAF6 inhibition could represent a new therapeutic strategy for human pancreatic cancer.

AB - Ninety percent of human pancreatic cancer is characterized by activating K-RAS mutations. TRAF6 is an oncogene that plays a vital role in K-RAS-mediated oncogenesis. We investigated the synergistic effect of combining ionizing radiation (IR) and proteasome inhibitor (MG132). Furthermore, following combined treatment with IR and MG132, we analyzed the expression of TRAF6 and the mechanism of human pancreatic cancer cell death in vitro and in an orthotopic pancreatic cancer mouse model. The combined treatment groups displayed synergistic cell killing effects and induced endoplasmic reticulum stress in human pancreatic cancer cells. The combined treatment groups were characterized by enhanced cytotoxicity, which resulted from increased autophagy induction through the inhibition of TRAF6. Significantly reduced cytotoxicity was observed following MG132 and IR treatment of MIA PaCa-2 cells pre-treated with 3-MA (an autophagy inhibitor). Down-regulation of TRAF6 led to a significant increase in apoptosis and autophagy. In an orthotopic xenograft model of SCID mice, combination MG132 and IR therapy resulted in a significant increase in the tumor growth delay time and a decreased tumor tissue expression of TRAF6. IR combined with a proteasome inhibitor or TRAF6 inhibition could represent a new therapeutic strategy for human pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84937643293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937643293&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2015.05.025

DO - 10.1016/j.canlet.2015.05.025

M3 - Article

C2 - 26052093

AN - SCOPUS:84937643293

VL - 365

SP - 229

EP - 239

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -